Skip to main content
Clinical Trials/NCT05159713
NCT05159713
Completed
Not Applicable

Randomized Control Trial to Evaluate the Efficacy of a Digital Mental Health Intervention Embedded in Routine Care Compared to Treatment As Usual in Adolescents and Young Adults with Moderate Depressive Symptoms

University of Pittsburgh3 sites in 1 country185 target enrollmentJune 1, 2022
ConditionsDepression

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
University of Pittsburgh
Enrollment
185
Locations
3
Primary Endpoint
Change in depression severity
Status
Completed
Last Updated
last year

Overview

Brief Summary

Randomized Controlled Trial comparing a coach-enhanced digital cognitive behavioral intervention (d-CBI) (RxWell) + treatment as usual (TAU) versus TAU alone for moderate depression as determined by Patient Health Questionnaire (PHQ-9) threshold as part of routine pediatric care.

The study will be completed in pediatric practices with embedded behavioral therapists across 3 institutions (Children's Hospital of Pittsburgh, Boston Children's Hospital, Rady Children's Hospital, San Diego).

Detailed Description

After consent, participants will be further screened to determine eligibility. They will complete a brief Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5) (SCID). If someone has been hospitalized in the past 3 months for dangerousness, or is diagnosed with severe current psychiatric disorders based on SCID V (Clinical Trials Version) for bipolar disorder, current substance misuse or dependence, or thought disorder they will not be eligible for this study and will be referred back to the clinician for further support. PARTICIPANT PROCEDURES: All participants who are eligible for this study, consent to participate, and are randomized to one of the two arms (dCBI+TAU or TAU) will be asked to complete self-report and blinded clinician administered measures on three occasions over 12 weeks (baseline, 6-, and 12-week time points). At enrollment and prior to randomization, each participant will be assigned a unique Study ID that will be used to code all data collected for research purposes. Participants will be asked to complete self-report assessments via 1) self-administered completion of assessments through REDCap Cloud (i.e., online); 2) over the phone with a member of the Research Team who will enter the participant's responses into a secure web-based portal (REDCap Cloud).

Registry
clinicaltrials.gov
Start Date
June 1, 2022
End Date
August 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eva Szigethy

Professor of Psychiatry and Medicine

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • Age 16-22 inclusive recruited from outpatient pediatric clinic visit.
  • Meeting positive screen criteria depression by PHQ-9 criteria (score greater than or equal to10).
  • English-speaking (participant)
  • Smart phone access

Exclusion Criteria

  • Extremely severe depression (PHQ-9 greater than 24; or active suicidal plan).
  • Current dangerousness (based on Treatment for Adolescents for Depression Study (TADS) study criteria, 2004). Hospitalized for dangerousness within 3 months; Suicide attempt requiring medical attention within 3 months.
  • Severe, current psychiatric disorders based on SCID V (Clinical Trials Version) for bipolar disorder, current substance misuse or dependence, thought disorder. Research coordinators who are trained to fidelity threshold will complete this measure with the patient.

Outcomes

Primary Outcomes

Change in depression severity

Time Frame: 12 weeks

Children's Depression Rating Scale-Revised (CDRS-R) will be administered by a blinded rater from baseline up to 12 weeks after baseline to evaluate the change in depression severity. The CDRS-R is a 17-item interview, which score can add up to between 17 and 113. A score of greater than or equal to 40 indicates depressive symptomatology, and a score of less than or equal to indicates remission.

Secondary Outcomes

  • Change in quality of life(12 weeks)
  • Change in depression severity; evidence of passive suicidal ideation(12 weeks)
  • Change in anxiety severity(12 weeks)
  • Change in general level of functioning(12 weeks)

Study Sites (3)

Loading locations...

Similar Trials